Investigational novel therapies for HBV infection (selected)
| Categories ofnovel therapies | Types and compounds | Clinical trial (Phase) | References |
|---|---|---|---|
| Direct-acting antivirals (DAAs) | Capsid assembly modulators (CAMs) | ||
| Bersacapavir (JNJ-6379) | Phase 2b | [67] | |
| Morphothiadin (GLS4) | Phase 2 | [68] | |
| EDP-514 | Phase 1 | [69] | |
| siRNA agents | |||
| JNJ-3989 | Phase 2b | [67] | |
| RG6346 | Phase 2 | [70] | |
| AB7-29-001 | Phase 2 | [71] | |
| Antisense oligonucleotides (ASOs) | |||
| Bepirovirsen (GSK32228836) | Phase 2 | [72] | |
| RO7062931 | Phase 1 | [73] | |
| HBV entry inhibitors | |||
| Bulevirtide | Phase 2 | [78] | |
| HBsAg inhibitors | |||
| REP2139 | Phase 2 | [73] | |
| Host-directed antivirals (HDAs) | Immunomodulators, innate immune response | ||
| RO7020531 | Phase 1 | [74] | |
| Selgantolimod | Phase 2 | [75] | |
| Immunomodulators, adaptive immune response | |||
| Epcoritamab | Phase 2a | [68] | |
| Therapeutic vaccines | |||
| BRII-179 | Phase 2 | [76] |